Comparative molecular analysis of primary and secondary MH
| . | Alterations in the MAPK pathway . | PTPN11 mutations . | TP53 mutation . | Mutations in TET2, ASXL1 or DNMT3A . |
|---|---|---|---|---|
| Total | n = 50/71 (m.d.: 67) (70%) | n = 10/64 (m.d.: 74) (16%) | n = 9/63 (m.d.: 75) (14%) | n = 13/63 (m.d.: 75) (21%) |
| Primary MH | n = 22/40 (m.d.: 49) (55%) | n = 10/37 (m.d.: 52) (27%) | n = 3/36 (m.d.: 53) (8%) | n = 7/36 (m.d.: 53) (19%) |
| Secondary MH | n = 28/31 (m.d.: 18) (90%) | n = 0/27 (m.d.: 22) (0%) | n = 6/27 (m.d.: 22) (22%) | n = 6/27 (m.d.: 22) (22%) |
| P value | 0.0012 (χ2 test) | 0.0035 (Fisher exact test) | 0.1550 (Fisher exact test) | 0.7875 (χ2 test) |
| . | Alterations in the MAPK pathway . | PTPN11 mutations . | TP53 mutation . | Mutations in TET2, ASXL1 or DNMT3A . |
|---|---|---|---|---|
| Total | n = 50/71 (m.d.: 67) (70%) | n = 10/64 (m.d.: 74) (16%) | n = 9/63 (m.d.: 75) (14%) | n = 13/63 (m.d.: 75) (21%) |
| Primary MH | n = 22/40 (m.d.: 49) (55%) | n = 10/37 (m.d.: 52) (27%) | n = 3/36 (m.d.: 53) (8%) | n = 7/36 (m.d.: 53) (19%) |
| Secondary MH | n = 28/31 (m.d.: 18) (90%) | n = 0/27 (m.d.: 22) (0%) | n = 6/27 (m.d.: 22) (22%) | n = 6/27 (m.d.: 22) (22%) |
| P value | 0.0012 (χ2 test) | 0.0035 (Fisher exact test) | 0.1550 (Fisher exact test) | 0.7875 (χ2 test) |
m.d., missing data.